Malignant Ovarian Epithelial Tumor — Trials

Malignant Ovarian Epithelial Tumor — Trials · CancerIndex

Clinical trials

Registered studies

897 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 270
Recruiting: 140
Ph III recruiting: 16
Growth YoY: +23.1%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (145)

clinicaltrialsPublishedShowing 351–400 of 897 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02489903	RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)	completed	Phase 2	139	EpicentRx, Inc.INDUSTRY	1	Mar 17, 2025	clinicaltrials
NCT03268382	p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246	completed	Phase 2	36	Aprea TherapeuticsINDUSTRY	3	Mar 17, 2025	clinicaltrials